|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Danish Headache Center |
| Information provided by: | Danish Headache Center |
| ClinicalTrials.gov Identifier: | NCT00291395 |
Purpose
Before , during and after intravenous administration of PGI2 we score/measure headache, rCBF, blood flow in middle cerebral artery and diameter of superficial temporal artery/radial artery and correlate that to known patophysiology of headache to see if PGI2 is involved in headache pathophysiology.
| Condition | Intervention | Phase |
|
Headache Migraine |
Drug: PGI2 |
Phase I |
| Genetics Home Reference related topics: | familial hemiplegic migraine |
| MedlinePlus related topics: | Headache Migraine |
| ChemIDplus related topics: | Epoprostenol Epoprostenol sodium |
| Study Type: | Interventional |
| Study Design: | Randomized, Double-Blind, Placebo Control, Crossover Assignment |
Eligibility
| Ages Eligible for Study: | 18 Years to 40 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | KA05055 |
| First Received: | February 13, 2006 |
| Last Updated: | October 25, 2006 |
| ClinicalTrials.gov Identifier: | NCT00291395 |
| Health Authority: | Denmark: Ethics Committee |
|
|
|